RHHBF Roche Holding AG

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, obesity, ophthalmology, osteoporosis, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, and women's health, as well oncology. In addition, it provides supplies a array of instruments and reagents, and test kits for use in the diverse research market. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol SE:RO.

$379.75    OTCQX
As of 07/01/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  Switzerland
Country of incorporation:  
IPO date:  07/19/2001
Outstanding shares:  106,691,000
Average volume:  74
Market cap:   $40,515,907,250
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy